AstraZeneca to acquire global rights for lung cancer drug Zegfrovy

Under the terms of the agreement, Dizal will receive an upfront payment of $600 million, with potential milestone payments reaching an additional $900 million. The company is also set to receive tiered royalties on global sales of the drug. The transaction is expected to close in the second half of 2026, pending regulatory clearances.

Zegfrovy is currently approved in the U.S. and China for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed following platinum-based chemotherapy. The drug’s potential is supported by the multinational Phase III WU-KONG28 study, which recently demonstrated its efficacy in first-line treatment settings. These findings were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. Both the U.S. FDA and China’s Center for Drug Evaluation have granted the drug Breakthrough Therapy Designation for this indication.